Literature DB >> 12480814

Apoptosis and cellular activation in the pathogenesis of acute vascular rejection.

Zoie E Holzknecht1, Karisha L Kuypers, Timothy B Plummer, Josie Williams, Matilda Bustos, Gregory J Gores, Gregory J Brunn, Jeffrey L Platt.   

Abstract

Acute vascular or humoral rejection, a vexing outcome of organ transplantation, has been attributed by some to activation and by others to apoptosis of endothelial cells in the graft. We asked which of these processes causes acute vascular rejection by tracing the processes during the development of acute vascular rejection in porcine cardiac xenografts performed in baboons. Apoptosis, assayed by terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL), expression of activated caspase-3, and proapoptotic genes Bax and Bcl-x(L), was not detected until acute vascular rejection was well advanced, and even then, apoptosis was largely confined to myocytes. Activation of the endothelium, as evidenced by expansion of rough endoplasmic reticulum and increased ribosomal antigen and phospho-p70 S6 kinase, occurred early in the course of acute vascular rejection and progressed through the disease process. These findings suggest that acute vascular rejection is caused by an active metabolic process and not by apoptosis in the endothelium.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12480814     DOI: 10.1161/01.res.0000046236.20251.fa

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  9 in total

1.  Protection of porcine endothelial cells against apoptosis with interleukin-4.

Authors:  Sylvester M Black; Barbara A Benson; Damé Idossa; Gregory M Vercellotti; Agustin P Dalmasso
Journal:  Xenotransplantation       Date:  2011 Nov-Dec       Impact factor: 3.907

2.  Rejection severity directly correlates with myocyte apoptosis in pig-to-baboon cardiac xenotransplantation.

Authors:  Joel G R Weaver; Christopher G A McGregor; Henry D Tazelaar; Andrew D Badley
Journal:  J Heart Lung Transplant       Date:  2005-07       Impact factor: 10.247

Review 3.  Accommodation of grafts: implications for health and disease.

Authors:  Amy H Tang; Jeffrey L Platt
Journal:  Hum Immunol       Date:  2007-05-15       Impact factor: 2.850

4.  Current status of animal-to-human transplantation.

Authors:  Robert Zhong; Jeffrey L Platt
Journal:  Expert Opin Biol Ther       Date:  2005-11       Impact factor: 4.388

5.  Expression of tissue factor and initiation of clotting by human platelets and monocytes after incubation with porcine endothelial cells.

Authors:  Chih Che Lin; Daxin Chen; John H McVey; David K C Cooper; Anthony Dorling
Journal:  Transplantation       Date:  2008-09-15       Impact factor: 4.939

6.  Thrombotic microangiopathy associated with humoral rejection of cardiac xenografts from alpha1,3-galactosyltransferase gene-knockout pigs in baboons.

Authors:  Akira Shimizu; Yosuke Hisashi; Kenji Kuwaki; Yau-Lin Tseng; Frank J M F Dor; Stuart L Houser; Simon C Robson; Henk-Jan Schuurman; David K C Cooper; David H Sachs; Kazuhiko Yamada; Robert B Colvin
Journal:  Am J Pathol       Date:  2008-05-08       Impact factor: 4.307

7.  Anti-MHC class I antibody activation of proliferation and survival signaling in murine cardiac allografts.

Authors:  Peter T Jindra; Aileen Hsueh; Longshen Hong; David Gjertson; Xiu-Da Shen; Feng Gao; Julie Dang; Paul S Mischel; William M Baldwin; Michael C Fishbein; Jerzy W Kupiec-Weglinski; Elaine F Reed
Journal:  J Immunol       Date:  2008-02-15       Impact factor: 5.422

Review 8.  Coagulation dysregulation as a barrier to xenotransplantation in the primate.

Authors:  Chih Che Lin; David K C Cooper; Anthony Dorling
Journal:  Transpl Immunol       Date:  2008-11-10       Impact factor: 1.708

Review 9.  Minimizing Ischemia Reperfusion Injury in Xenotransplantation.

Authors:  Parth M Patel; Margaret R Connolly; Taylor M Coe; Anthony Calhoun; Franziska Pollok; James F Markmann; Lars Burdorf; Agnes Azimzadeh; Joren C Madsen; Richard N Pierson
Journal:  Front Immunol       Date:  2021-09-09       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.